Raras
Buscar doenças, sintomas, genes...
Câncer colorretal hereditário sem polipose
ORPHA:443909CID-10 · C18DOENÇA RARA

Uma condição que aumenta o risco de ter câncer, caracterizada pelo desenvolvimento de câncer colorretal (de intestino grosso) que não está ligado à polipose colorretal (uma condição com muitos pólipos no intestino), câncer de endométrio (no útero) e vários outros tipos de câncer (como o de ovário, estômago, vias biliares, intestino delgado e vias urinárias), e que, geralmente, são diagnosticados em idade precoce.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma condição que aumenta o risco de ter câncer, caracterizada pelo desenvolvimento de câncer colorretal (de intestino grosso) que não está ligado à polipose colorretal (uma condição com muitos pólipos no intestino), câncer de endométrio (no útero) e vários outros tipos de câncer (como o de ovário, estômago, vias biliares, intestino delgado e vias urinárias), e que, geralmente, são diagnosticados em idade precoce.

Pesquisas ativas
5 ensaios
149 total registrados no ClinicalTrials.gov
Publicações científicas
236 artigos
Último publicado: 2025 Sep
Medicamentos
6 registrados
ASPIRIN, BEVACIZUMAB, FLUOROURACIL

Tem tratamento?

6 medicamentos registrados
Ver detalhes, fases e interações →
ASPIRINBEVACIZUMABFLUOROURACILMESALAMINENAPROXENATORVASTATIN
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C18
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
13 sintomas
🧠
Neurológico
9 sintomas
🦴
Ossos e articulações
4 sintomas
🫘
Rins
4 sintomas
📏
Crescimento
3 sintomas
🧬
Pele e cabelo
2 sintomas

+ 32 sintomas em outras categorias

Características mais comuns

Comportamento atípico
Convulsão
Carcinoma de mama
Neoplasia da pele
Enxaqueca
Câncer de estômago
72sintomas
Sem dados (72)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 72 características clínicas mais associadas, ordenadas por frequência.

Comportamento atípicoAtypical behavior
ConvulsãoSeizure
Carcinoma de mamaBreast carcinoma
Neoplasia da peleNeoplasm of the skin
EnxaquecaMigraine

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico236PubMed
Últimos 10 anos17publicações
Pico20235 papers
Linha do tempo
2025Hoje · 2026🧪 1994Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

20 genes identificados com associação a esta condição.

ATMSerine-protein kinase ATMCandidate gene tested inTolerante
FUNÇÃO

Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). Recognizes the substrate c

LOCALIZAÇÃO

NucleusCytoplasmic vesicleCytoplasm, cytoskeleton, microtubule organizing center, centrosomePeroxisome matrix

VIAS BIOLÓGICAS (5)
DNA Damage/Telomere Stress Induced SenescenceSensing of DNA Double Strand BreaksTP53 Regulates Transcription of DNA Repair GenesMeiotic recombinationRegulation of HSF1-mediated heat shock response
MECANISMO DE DOENÇA

Ataxia telangiectasia

A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.

OUTRAS DOENÇAS (9)
ataxia telangiectasiaATM-related cancer predispositionfamilial colorectal cancer type XB-cell chronic lymphocytic leukemia
HGNC:795UniProt:Q13315
MSH6DNA mismatch repair protein Msh6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstrea

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (2)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)Defective Mismatch Repair Associated With MSH2
MECANISMO DE DOENÇA

Lynch syndrome 5

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
40.1 TPM
Testículo
29.0 TPM
Útero
28.4 TPM
Linfócitos
26.3 TPM
Cervix Endocervix
21.9 TPM
OUTRAS DOENÇAS (5)
mismatch repair cancer syndrome 3Lynch syndrome 5Lynch syndromemismatch repair cancer syndrome
HGNC:7329UniProt:P52701
PMS1PMS1 protein homolog 1Candidate gene tested inTolerante
FUNÇÃO

Probably involved in the repair of mismatches in DNA

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
31.8 TPM
Cervix Ectocervix
17.6 TPM
Linfócitos
17.5 TPM
Cervix Endocervix
16.8 TPM
Fibroblastos
15.1 TPM
OUTRAS DOENÇAS (1)
Lynch syndrome
HGNC:9121UniProt:P54277
POLD1DNA polymerase delta catalytic subunitCandidate gene tested inTolerante
FUNÇÃO

As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair (PubMed:16510448, PubMed:19074196, PubMed:20334433, PubMed:24022480, PubMed:24035200, PubMed:31449058). Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities (PubMed:16510448, PubMed:19074196, PubMed:20334433, PubMed:24022480, PubMed:24035200). Req

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Cytosolic iron-sulfur cluster assembly
MECANISMO DE DOENÇA

Colorectal cancer 10

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
59.1 TPM
Testículo
30.1 TPM
Tireoide
22.1 TPM
Baço
21.6 TPM
Útero
20.2 TPM
OUTRAS DOENÇAS (5)
mandibular hypoplasia-deafness-progeroid syndromeimmunodeficiency 120Polymerase proofreading-related adenomatous polyposisfamilial colorectal cancer type X
HGNC:9175UniProt:P28340
MUTYHAdenine DNA glycosylaseCandidate gene tested inTolerante
FUNÇÃO

Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities

LOCALIZAÇÃO

NucleusMitochondrion

VIAS BIOLÓGICAS (3)
Cleavage of the damaged purineRecognition and association of DNA glycosylase with site containing an affected purineDisplacement of DNA glycosylase by APEX1
MECANISMO DE DOENÇA

Familial adenomatous polyposis 2

A condition characterized by the development of multiple colorectal adenomatous polyps, benign neoplasms derived from glandular epithelium. Some affected individuals may develop colorectal carcinoma.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
37.8 TPM
Cérebro - Hemisfério cerebelar
37.5 TPM
Tireoide
27.4 TPM
Nervo tibial
26.5 TPM
Cervix Ectocervix
25.8 TPM
OUTRAS DOENÇAS (3)
gastric cancerfamilial adenomatous polyposis 2familial colorectal cancer type X
HGNC:7527UniProt:Q9UIF7
CHEK2Serine/threonine-protein kinase Chk2Candidate gene tested inTolerante
FUNÇÃO

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T] (PubMed:37943659). Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, in

LOCALIZAÇÃO

NucleusNucleus, PML bodyNucleus, nucleoplasm

VIAS BIOLÓGICAS (2)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaksG2/M DNA damage checkpoint
MECANISMO DE DOENÇA

Tumor predisposition syndrome 4

A disorder characterized by an increased risk for developing various types of benign and/or malignant neoplasms that arise at an accelerated rate and in different organs.

OUTRAS DOENÇAS (6)
obsolete Li-Fraumeni syndrome 2bone osteosarcomaprostate cancer, hereditaryhereditary breast ovarian cancer syndrome
HGNC:16627UniProt:O96017
MSH2DNA mismatch repair protein Msh2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (5)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)TP53 Regulates Transcription of DNA Repair GenesMismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)Defective Mismatch Repair Associated With MSH3Defective Mismatch Repair Associated With MSH6
MECANISMO DE DOENÇA

Lynch syndrome 1

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
34.5 TPM
Cérebro - Hemisfério cerebelar
23.4 TPM
Testículo
21.1 TPM
Cerebelo
19.8 TPM
Fibroblastos
19.7 TPM
OUTRAS DOENÇAS (5)
Muir-Torre syndromemismatch repair cancer syndrome 2Lynch syndrome 1Lynch syndrome
HGNC:7325UniProt:P43246
PIK3CAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformCandidate gene tested inAltamente restrito
FUNÇÃO

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, PubMed:28676499). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1,

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Signaling by LTK in cancerNephrin family interactionsIRS-mediated signallingTie2 SignalingDAP12 signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
23.2 TPM
Linfócitos
22.4 TPM
Nervo tibial
21.4 TPM
Tecido adiposo
20.5 TPM
Fibroblastos
20.5 TPM
OUTRAS DOENÇAS (28)
seborrheic keratosismegalodactylyovarian cancerhepatocellular carcinoma
HGNC:8975UniProt:P42336
RPS20Small ribosomal subunit protein uS10Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the small ribosomal subunit (PubMed:23636399). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1353.5 TPM
Linfócitos
957.4 TPM
Cervix Ectocervix
885.0 TPM
Cervix Endocervix
834.7 TPM
Tecido adiposo
749.1 TPM
OUTRAS DOENÇAS (2)
familial colorectal cancer type XDiamond-Blackfan anemia
HGNC:10405UniProt:P60866
BRCA2Breast cancer type 2 susceptibility proteinCandidate gene tested inTolerante
FUNÇÃO

Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (3)
Presynaptic phase of homologous DNA pairing and strand exchangeHDR through MMEJ (alt-NHEJ)Meiotic recombination
MECANISMO DE DOENÇA

Breast cancer

A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

OUTRAS DOENÇAS (17)
Wilms tumor 1Fanconi anemia complementation group D1breast-ovarian cancer, familial, susceptibility to, 2BRCA2-related cancer predisposition
HGNC:1101UniProt:P51587
MLH1DNA mismatch repair protein Mlh1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points f

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (5)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)TP53 Regulates Transcription of DNA Repair GenesMeiotic recombinationDefective Mismatch Repair Associated With PMS2
MECANISMO DE DOENÇA

Lynch syndrome 2

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
48.5 TPM
Testículo
44.5 TPM
Fibroblastos
33.8 TPM
Pituitária
33.4 TPM
Cervix Ectocervix
33.1 TPM
OUTRAS DOENÇAS (6)
Lynch syndrome 2Muir-Torre syndromeLynch syndromeLynch syndrome 1
HGNC:7127UniProt:P40692
SEMA4ASemaphorin-4ACandidate gene tested inTolerante
FUNÇÃO

Cell surface receptor for PLXNB1, PLXNB2, PLXNB3 and PLXND1 that plays an important role in cell-cell signaling (By similarity). Regulates glutamatergic and GABAergic synapse development (By similarity). Promotes the development of inhibitory synapses in a PLXNB1-dependent manner and promotes the development of excitatory synapses in a PLXNB2-dependent manner (By similarity). Plays a role in priming antigen-specific T-cells, promotes differentiation of Th1 T-helper cells, and thereby contributes

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Other semaphorin interactions
MECANISMO DE DOENÇA

Retinitis pigmentosa 35

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
85.9 TPM
Linfócitos
67.2 TPM
Tireoide
40.6 TPM
Skin Not Sun Exposed Suprapubic
38.2 TPM
Esôfago - Mucosa
36.5 TPM
OUTRAS DOENÇAS (5)
retinitis pigmentosa 35cone-rod dystrophy 10familial colorectal cancer type Xcone-rod dystrophy
HGNC:10729UniProt:Q9H3S1
NPATProtein NPATCandidate gene tested inRestrito
FUNÇÃO

Transcription regulator required for progression through the G1 and S phases of the cell cycle and for S phase entry (PubMed:12665581, PubMed:15555599, PubMed:9472014). Acts as a key transcription regulator of histones (PubMed:10995386, PubMed:10995387, PubMed:12724424, PubMed:14585971, PubMed:14612403, PubMed:15988025, PubMed:16131487, PubMed:17163457, PubMed:25339177, PubMed:40516528, PubMed:40516529). Activates transcription of the histone H2A, histone H2B, histone H3 and histone H4 genes in

LOCALIZAÇÃO

NucleusNucleus, Cajal bodyChromosome

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
18.6 TPM
Ovário
9.5 TPM
Cervix Endocervix
9.1 TPM
Fibroblastos
8.8 TPM
Nervo tibial
8.7 TPM
OUTRAS DOENÇAS (1)
familial colorectal cancer type X
HGNC:7896UniProt:Q14207
MLH3DNA mismatch repair protein Mlh3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probably involved in the repair of mismatches in DNA

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Meiotic recombination
MECANISMO DE DOENÇA

Hereditary non-polyposis colorectal cancer 7

An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
16.3 TPM
Nervo tibial
15.0 TPM
Cervix Endocervix
14.7 TPM
Cervix Ectocervix
13.7 TPM
Fallopian Tube
12.0 TPM
OUTRAS DOENÇAS (3)
colorectal cancer, hereditary nonpolyposis, type 7colorectal cancerendometrial cancer
HGNC:HGNC:7128UniProt:Q9UHC1
PMS2Mismatch repair endonuclease PMS2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the post-replicative DNA mismatch repair system (MMR) (PubMed:30653781, PubMed:35189042). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)TP53 Regulates Transcription of DNA Repair GenesDefective Mismatch Repair Associated With MLH1
MECANISMO DE DOENÇA

Lynch syndrome 4

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.4 TPM
Cérebro - Hemisfério cerebelar
17.8 TPM
Cerebelo
16.4 TPM
Fibroblastos
15.2 TPM
Skin Sun Exposed Lower leg
14.0 TPM
OUTRAS DOENÇAS (4)
mismatch repair cancer syndrome 4Lynch syndrome 4mismatch repair cancer syndromeLynch syndrome
HGNC:9122UniProt:P54278
TGFBR2TGF-beta receptor type-2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extr

LOCALIZAÇÃO

Cell membraneMembrane raftSecreted

VIAS BIOLÓGICAS (8)
TGF-beta receptor signaling activates SMADsDownregulation of TGF-beta receptor signalingUCH proteinasesTGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)TGFBR1 LBD Mutants in Cancer
MECANISMO DE DOENÇA

Hereditary non-polyposis colorectal cancer 6

An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
377.2 TPM
Tecido adiposo
319.8 TPM
Adipose Visceral Omentum
301.0 TPM
Mama
271.8 TPM
Nervo tibial
261.1 TPM
OUTRAS DOENÇAS (7)
Loeys-Dietz syndrome 2esophageal cancercolorectal cancer, hereditary nonpolyposis, type 6familial thoracic aortic aneurysm and aortic dissection
HGNC:11773UniProt:P37173
BMPR1ABone morphogenetic protein receptor type-1ACandidate gene tested inAltamente restrito
FUNÇÃO

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. May promote the expression of HAMP, potentially via its interaction with

LOCALIZAÇÃO

Cell membraneCell surface

VIAS BIOLÓGICAS (1)
Signaling by BMP
MECANISMO DE DOENÇA

Juvenile polyposis syndrome

Autosomal dominant gastrointestinal hamartomatous polyposis syndrome in which patients are at risk for developing gastrointestinal cancers. The lesions are typified by a smooth histological appearance, predominant stroma, cystic spaces and lack of a smooth muscle core. Multiple juvenile polyps usually occur in a number of Mendelian disorders. Sometimes, these polyps occur without associated features as in JPS; here, polyps tend to occur in the large bowel and are associated with an increased risk of colon and other gastrointestinal cancers.

VIAS REACTOME (1)
OUTRAS DOENÇAS (6)
juvenile polyposis syndromepolyposis syndrome, hereditary mixed, 2hereditary mixed polyposis syndromefamilial colorectal cancer type X
HGNC:1076UniProt:P36894
POLEDNA polymerase epsilon catalytic subunit ACandidate gene tested inTolerante
FUNÇÃO

Catalytic component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in chromosomal DNA replication (By similarity). Required during synthesis of the leading DNA strands at the replication fork, binds at/or near replication origins and moves along DNA with the replication fork (By similarity). Has 3'-5' proofreading exonuclease activity that corrects errors arising during DNA replication (By similarity). Involved in DNA synthesis during DNA repair (PubMed:20227374, PubMed:27

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
HDR through Homologous Recombination (HRR)PCNA-Dependent Long Patch Base Excision RepairRecognition of DNA damage by PCNA-containing replication complexTermination of translesion DNA synthesisDual incision in TC-NER
MECANISMO DE DOENÇA

Colorectal cancer 12

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. CRCS12 is characterized by a high-penetrance predisposition to the development of colorectal adenomas and carcinomas, with a variable tendency to develop multiple and large tumors. Onset is usually before age 40 years. The histologic features of the tumors are unremarkable.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
76.9 TPM
Cérebro - Hemisfério cerebelar
62.4 TPM
Testículo
50.2 TPM
Baço
33.3 TPM
Linfócitos
30.5 TPM
OUTRAS DOENÇAS (6)
intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiencyfacial dysmorphism-immunodeficiency-livedo-short stature syndromePolymerase proofreading-related adenomatous polyposisIMAGe syndrome
HGNC:9177UniProt:Q07864
KRASGTPase KRasCandidate gene tested inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
EPCAMEpithelial cell adhesion moleculeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E

LOCALIZAÇÃO

Lateral cell membraneCell junction, tight junction

VIAS BIOLÓGICAS (6)
Cell surface interactions at the vascular wallDevelopmental Lineage of Mammary Gland Luminal Epithelial CellsDevelopmental Lineage of Mammary Gland Alveolar CellsDevelopmental Lineage of Mammary Stem CellsDevelopmental Lineage of Mammary Gland Myoepithelial Cells
MECANISMO DE DOENÇA

Diarrhea 5, with tufting enteropathy, congenital

An intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon transverso
347.0 TPM
Intestino delgado
309.3 TPM
Tireoide
260.1 TPM
Rim - Medula
171.6 TPM
Pituitária
134.9 TPM
OUTRAS DOENÇAS (3)
Lynch syndrome 8congenital diarrhea 5 with tufting enteropathyLynch syndrome
HGNC:11529UniProt:P16422

Medicamentos e terapias

ASPIRINPhase 3

Mecanismo: Cyclooxygenase inhibitor

BEVACIZUMABPhase 3

Mecanismo: Vascular endothelial growth factor A inhibitor

FLUOROURACILPhase 3

Mecanismo: Thymidylate synthase inhibitor

MESALAMINEPhase 2

Mecanismo: Arachidonate 5-lipoxygenase inhibitor

NAPROXENPhase 1

Mecanismo: Cyclooxygenase inhibitor

ATORVASTATINPhase 0.5

Mecanismo: HMG-CoA reductase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

14,476 variantes patogênicas registradas no ClinVar.

🧬 ATM: NM_000051.4(ATM):c.3308_3309del (p.Asp1103fs) ()
🧬 ATM: NM_000051.4(ATM):c.2374A>T (p.Lys792Ter) ()
🧬 ATM: NM_000051.4(ATM):c.7368dup (p.Glu2457fs) ()
🧬 ATM: NM_000051.4(ATM):c.4173_4174delinsTTTA (p.Tyr1392fs) ()
🧬 ATM: NM_000051.4(ATM):c.843_846del (p.Glu281fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 658 variantes classificadas pelo ClinVar.

526
132
Patogênica (79.9%)
VUS (20.1%)
VARIANTES MAIS SIGNIFICATIVAS
MSH2: NM_000251.3(MSH2):c.2381_2382insCT (p.Pro795fs) [Pathogenic]
PMS2: NC_000007.13:g.(6022623_6026389)_(6043690_6045522)del [Pathogenic]
PMS2: NC_000007.13:g.(?_6010555)_(6045663_6048627)del [Pathogenic]
MSH6: NM_000179.3(MSH6):c.2276_2277del (p.Leu759fs) [Pathogenic]
MSH2: NM_000251.3(MSH2):c.1025_1026insA (p.Val342_Asn343insTer) [Likely pathogenic]

Vias biológicas (Reactome)

154 vias biológicas associadas aos genes desta condição.

DNA Damage/Telomere Stress Induced Senescence Regulation of HSF1-mediated heat shock response Autodegradation of the E3 ubiquitin ligase COP1 HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Caspase Activators and Caspases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Meiotic recombination Pexophagy Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Defective Mismatch Repair Associated With MSH2 Defective Mismatch Repair Associated With MSH6 Recognition of DNA damage by PCNA-containing replication complex Polymerase switching on the C-strand of the telomere Processive synthesis on the C-strand of the telomere Telomere C-strand (Lagging Strand) Synthesis Removal of the Flap Intermediate from the C-strand Cytosolic iron-sulfur cluster assembly Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) PCNA-Dependent Long Patch Base Excision Repair Termination of translesion DNA synthesis Gap-filling DNA repair synthesis and ligation in GG-NER Dual Incision in GG-NER Dual incision in TC-NER Gap-filling DNA repair synthesis and ligation in TC-NER Polymerase switching Removal of the Flap Intermediate Processive synthesis on the lagging strand Recognition and association of DNA glycosylase with site containing an affected purine Cleavage of the damaged purine Displacement of DNA glycosylase by APEX1 Defective MUTYH substrate binding Defective MUTYH substrate processing Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Defective Mismatch Repair Associated With MSH3 PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis Major pathway of rRNA processing in the nucleolus and cytosol Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency SARS-CoV-1 modulates host translation machinery SARS-CoV-2 modulates host translation machinery Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA HDR through MMEJ (alt-NHEJ) Impaired BRCA2 translocation to the nucleus Impaired BRCA2 binding to SEM1 (DSS1) Defective Mismatch Repair Associated With MLH1 Defective Mismatch Repair Associated With PMS2 Other semaphorin interactions Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases TGFBR3 regulates TGF-beta signaling Signaling by BMP DNA replication initiation Activation of the pre-replicative complex SOS-mediated signalling Activation of RAS in B cells SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling GRB2 events in ERBB2 signaling EGFR Transactivation by Gastrin SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ca2+ pathway Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling Cell surface interactions at the vascular wall Attachment of bacteria to epithelial cells Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 21
1Fase 11
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 6 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Câncer colorretal hereditário sem polipose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

149 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
15 papers (10 anos)
#1

Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome): An Emerging Public Health Concern.

Health science reports2025 Sep

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dominant disorder caused by germline mutations in DNA mismatch repair (MMR) genes that confer increased lifetime risks for colorectal, endometrial, and other cancers. Lynch syndrome accounts for only 3%-5% of colorectal cancer cases; however, most patients with Lynch syndrome are not diagnosed, leading to missed opportunities for enhanced surveillance and preventive interventions. This study examined the molecular genetics, epidemiology, and shortcomings of conventional, selective screening strategies for Lynch syndrome. Universal tumor testing using MMR immunohistochemistry (IHC) or microsatellite instability (MSI) analyses is recommended for all newly diagnosed colorectal and endometrial cancers, with reflex BRAF/methylation testing applied to distinguish likely sporadic cases. We also need to consider essential components of coordinated Lynch syndrome management, including cascade screening of family members, electronic health record (EHR) integration, multidisciplinary care teams, and public education. Selective screening for Lynch syndrome, based on the age or family history, misses many cases, whereas universal tumor testing is more cost-effective for identifying more patients. In addition to genetic counseling, surveillance colonoscopy, prophylactic surgical measures, and psychosocial support, we must provide equitable access to these services for all potentially affected patients. Advances in technology, such as circulating tumor DNA (ctDNA) assays and polygenic risk scores, represent new methods for cancer screening and risk stratification. In summary, a coordinated, equity-centric public health model for Lynch syndrome should incorporate universal tumor testing, cascade screening, integration of clinical workflows, and community outreach. This framework could potentially turn the "underrecognized" aspect of Lynch syndrome into a "largely preventable" cancer syndrome. The proposed model could also represent a way to develop a broader strategy for other hereditary cancer syndromes, as future research focuses on scalable implementation, real-world cost-effectiveness, and genomic population screening.

#2

Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors.

International journal of molecular sciences2025 May 06

The integrity of the genome is maintained by mismatch repair (MMR) proteins that recognize and repair base mismatches and insertion/deletion errors generated during DNA replication and recombination. A defective MMR system results in genome-wide instability and the progressive accumulation of mutations. Tumors exhibiting deficient MMR (dMMR) and/or high levels of microsatellite instability (termed "microsatellite instability high", or MSI-H) have been shown to possess fundamental differences in clinical, pathological, and molecular characteristics, distinguishing them from their "microsatellite stable" (MSS) counterparts. Molecularly, they are defined by a high mutational burden, genetic instability, and a distinctive immune profile. Their distinct genetic and immunological profiles have made dMMR/MSI-H tumors particularly amenable to treatment with immune checkpoint inhibitors (ICIs). The ongoing development of biomarker-driven therapies and the evaluation of novel combinations of immune-based therapies, with or without the use of conventional cytotoxic treatment regimens, continue to refine treatment strategies with the goals of maximizing therapeutic efficacy and survival outcomes in this distinct patient population. Moreover, the resultant knowledge of the mechanisms by which these features are suspected to render these tumors more responsive, overall, to immunotherapy may provide information regarding the potential optimization of this therapeutic approach in tumors with proficient MMR (pMMR)/MSS tumors. Colorectal cancer is the third most common diagnosis and cause of cancer-related death in both sexes in the United States.  Worldwide and in the United States, colon and rectal cancers are the second most common cause of cancer-related mortality.  Incidence rates have been decreasing in Western countries, mostly due to the widespread use of colonoscopy screening. However, the condition's incidence among younger adults is increasing. Most colon cancer is sporadic, and approximately 5 percent are due to an inherited genetic mutation, mostly due to Lynch syndrome (hereditary nonpolyposis colon cancer or HNPCC) and familial adenomatous polyposis (FAP). The transition from normal colon epithelium to invasive cancer takes several years and most commonly follows a sequence characterized by the accumulation of genetic mutations, adenoma formation, and subsequent carcinogenesis (adenoma-carcinoma sequence). Certain cancers may follow alternative pathways, such as those involving DNA mismatch repair (MMR) and the BRAF gene. Colon cancer screening is recommended and may be performed using various modalities. Screening initiation and follow-up guidelines vary among organizations. Colon cancer diagnosis requires a tissue biopsy, usually obtained via colonoscopy. All newly diagnosed colon cancers should be screened for common genetic mutations, and a complete colonoscopy and baseline carcinoembryonic antigen (CEA) should be performed. Most patients with invasive cancer require a baseline chest and abdominopelvic computed tomography (CT) scan. Surgical resection is the main modality for localized early-stage colon cancer. The most important prognostic indicator is the pathological stage. Staging dictates the need for further therapy, which may include chemotherapy, immunotherapy, or, rarely, radiation. Surveillance after treatment is crucial in detecting metastatic disease and local recurrence, which may be curable with multimodality therapy. Palliative systemic therapy is reserved for nonresectable or widely metastatic disease to improve quality of life and survival. Hereditary nonpolyposis colorectal cancer (HNPCC), previously known as Lynch syndrome, is an autosomal dominant genetic disorder with varying degrees of penetrance. HNPCC is the most common cause of inherited colorectal cancer. This disease is characterized by a strong family history of related cancers, affecting first-degree relatives across at least 2 generations, with at least 1 case diagnosed before the age of 50. The primary genetic defect associated with HNPCC is a germline mutation in 1 of the mismatch repair (MMR) genes, particularly MLH1, MSH2, MSH6, or PMS2.  Individuals with HNPCC have a lifetime risk of colorectal cancer between 50% and 80%, often diagnosed before age 50, along with increased risks for other cancers, particularly endometrial (25%-60% risk), ovarian, stomach, and urinary tract cancers. Tumors associated with HNPCC typically exhibit microsatellite instability (MSI), which aids in diagnosis and treatment decisions. Early identification of affected individuals and appropriate screening significantly reduces the risk of malignancy. 

#3

Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms.

World journal of gastrointestinal oncology2024 Jun 15

In this editorial, I commented on the paper by Lin et al, published in this issue of the World Journal of Gastrointestinal Oncology. The work aimed at analysing the clinicopathologic characteristics and prognosis of synchronous and metachronous cancers in patients with dual primary gastric and colorectal cancer (CRC). The authors concluded the necessity for regular surveillance for metachronous cancer during postoperative follow-up and reported the prognosis is influenced by the gastric cancer (GC) stage rather than the CRC stage. Although surveillance was recommended in the conclusion, the authors did not explore this area in their study and did not include tests used for such surveillance. This editorial focuses on the most characterized gastrointestinal cancer susceptibility syndromes concerning dual gastric and CRCs. These include hereditary diffuse GC, familial adenomatous polyposis, hereditary nonpolyposis colon cancer, Lynch syndrome, and three major hamartomatous polyposis syndromes associated with CRC and GC, namely Peutz-Jeghers syndrome, juvenile polyposis syndrome, and PTEN hamartoma syndrome. Careful assessment of these syndromes/conditions, including inheritance, risk of gastric and colorectal or other cancer development, genetic mutations and recommended genetic investigations, is crucial for optimum management of these patients.

#4

The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.

Biomolecules2023 Oct 19

Transforming growth factor-β (TGF-β) has attracted attention as a tumor suppressor because of its potent growth-suppressive effect on epithelial cells. Dysregulation of the TGF-β signaling pathway is considered to be one of the key factors in carcinogenesis, and genetic alterations affecting TGF-β signaling are extraordinarily common in cancers of the gastrointestinal system, such as hereditary nonpolyposis colon cancer and pancreatic cancer. Accumulating evidence suggests that TGF-β is produced from various types of cells in the tumor microenvironment and mediates extracellular matrix deposition, tumor angiogenesis, the formation of CAFs, and suppression of the anti-tumor immune reaction. It is also being considered as a factor that promotes the malignant transformation of cancer, particularly the invasion and metastasis of cancer cells, including epithelial-mesenchymal transition. Therefore, elucidating the role of TGF-β signaling in carcinogenesis, cancer invasion, and metastasis will provide novel basic insight for diagnosis and prognosis and the development of new molecularly targeted therapies for gastrointestinal cancers. In this review, we outline an overview of the complex mechanisms and functions of TGF-β signaling. Furthermore, we discuss the therapeutic potentials of targeting the TGF-β signaling pathway for gastrointestinal cancer treatment and discuss the remaining challenges and future perspectives on targeting this pathway.

#5

Retinal Arterial Macroaneurysm in a Patient With Lynch Syndrome.

Journal of vitreoretinal diseases2023

Purpose: To describe a case of retinal arterial macroaneurysm (RAM) in a patient with hereditary nonpolyposis colon cancer (HNPCC)/Lynch syndrome. Methods: A case and its findings were analyzed. Results: A 68-year-old woman presented with a recent history of decreased near vision in the left eye. Both eyes had a visual acuity of 20/20 with normal intraocular pressure. The right retina was normal. The left retina had a focal dilation of the retinal arteriole with a surrounding hemorrhage and lipid in the inferonasal quadrant. The patient was diagnosed with RAM and was subsequently treated with focal laser photocoagulation. The patient had a medical history of stage 1 colon cancer associated with HNPCC/Lynch syndrome. Conclusions: Increased vascular network complexity has been reported in HNPCC/Lynch syndrome. This is the first report of a RAM in a patient with this genetic profile. Given the atypical presentation, there may be an association between HNPCC/Lynch syndrome and RAMs.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC55 artigos no totalmostrando 17

2025

Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome): An Emerging Public Health Concern.

Health science reports
2025

Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors.

International journal of molecular sciences
2024

Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms.

World journal of gastrointestinal oncology
2023

The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.

Biomolecules
2023

Retinal Arterial Macroaneurysm in a Patient With Lynch Syndrome.

Journal of vitreoretinal diseases
2023

[Surgical strategies for hereditary colorectal cancer].

Chirurgie (Heidelberg, Germany)
2023

Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry.

Frontiers in oncology
2023

Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations.

Cancers
2022

Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.

Genes
2022

Gastrointestinal polyposis with associated cutaneous manifestations.

Pathology
2021

Isolation and Characterization of Chemo-Resistant Stem Cells from a Mouse Model of Hereditary Non-Polyposis Colon Cancer.

Stem cells and cloning : advances and applications
2019

Detection of PMS2 Mutations by Screening Hereditary Nonpolyposis Colon Cancer Families from Denmark and Sweden.

Genetic testing and molecular biomarkers
2019

An Update on Inherited Colon Cancer and Gastrointestinal Polyposis.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
2017

A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability.

JAAD case reports
2017

Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.

International journal of molecular sciences
2016

Muir-Torre Syndrome Presenting as Sebaceous Adenocarcinoma and Invasive MSH6-Positive Colorectal Adenocarcinoma.

Case reports in oncology
2016

Mouse models of DNA mismatch repair in cancer research.

DNA repair
Ver todos os 55 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Câncer colorretal hereditário sem polipose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Câncer colorretal hereditário sem polipose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome): An Emerging Public Health Concern.
    Health science reports· 2025· PMID 40978308mais citado
  2. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors.
    International journal of molecular sciences· 2025· PMID 40362635mais citado
  3. Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms.
    World journal of gastrointestinal oncology· 2024· PMID 38994141mais citado
  4. The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.
    Biomolecules· 2023· PMID 37892233mais citado
  5. Retinal Arterial Macroaneurysm in a Patient With Lynch Syndrome.
    Journal of vitreoretinal diseases· 2023· PMID 37188208mais citado
  6. Colon Cancer.
    · 2026· PMID 29262132recente
  7. Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome).
    · 2026· PMID 33232092recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:443909(Orphanet)
  2. MONDO:0018630(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q783644(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Câncer colorretal hereditário sem polipose
Compêndio · Raras BR

Câncer colorretal hereditário sem polipose

ORPHA:443909 · MONDO:0018630
CID-10
C18 · Neoplasia maligna do cólon
Ensaios
5 ativos
Medicamentos
6 registrados
MedGen
UMLS
C0009405
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades